Zobrazeno 1 - 10
of 503
pro vyhledávání: '"Monoclonal antibodies (mAbs)"'
Autor:
Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M. Ismail, Adham Ezz El-Regal Mahmoud, Walid F. Elkhatib, Heba Aboul-Ella
Publikováno v:
Molecular Biomedicine, Vol 5, Iss 1, Pp 1-44 (2024)
Abstract Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth
Externí odkaz:
https://doaj.org/article/d8db5e7cec4d4870a337c03fbb191bb3
Autor:
Hongyu Qiu, Xin-Yong Yuan, Kimberly Holloway, Heidi Wood, Teresa Cabral, Chris Grant, Peter McQueen, Garrett Westmacott, Daniel R. Beniac, Lisa Lin, Michael Carpenter, Darwyn Kobasa, Tom Gräfenhan, Ian Wayne Cheney
Publikováno v:
Heliyon, Vol 10, Iss 15, Pp e35325- (2024)
Rapid antigen test (RAT) is widely used for SARS-CoV-2 infection diagnostics. However, test sensitivity has decreased recently due to the emergence of the Omicron variant and its sublineages. Here we developed a panel of SARS-CoV-2 nucleocapsid prote
Externí odkaz:
https://doaj.org/article/58d0d5e57f6643e6912fcacc854a3573
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
Maedi-visna virus (MVV) and caprine arthritis encephalitis virus (CAEV) are members of a group of genetically highly homologous lentiviruses collectively referred to as small ruminant lentiviruses (SRLVs). SRLVs can infect sheep, goats and other smal
Externí odkaz:
https://doaj.org/article/e368d6aa603945a9a0c8ac1f68a1a0d0
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Autor:
Anns Mahboob, Hasan Ali, AlJazi AlNaimi, Mahmoud Yousef, Mlaak Rob, Nawaf Ahmad Al-Muhannadi, Degiri Kalana Lasanga Senevirathne, Ali Chaari
Publikováno v:
Cells, Vol 13, Iss 18, p 1527 (2024)
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are two neurodegenerative diseases posing a significant disease burden due to their increasing prevalence and socio-economic cost. Traditional therapeutic approaches for these diseases exist b
Externí odkaz:
https://doaj.org/article/91228e5a7e9d4353b30225208293d4d0
Autor:
Hanrong Zhou, Mingxia Sun, Shibo Su, Liang Meng, Wei Yang, Lan Yang, Xinqi Shi, Xin Li, Haiwei Wang, Hongwei Ma, Xuehui Cai, Yan-Dong Tang, Tongqing An, Fandan Meng
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
Senecavirus A (SVA) is an important emerging swine pathogen that causes vesicular lesions in swine and acute death in newborn piglets. VP2 plays a significant role in the production of antibodies, which can be used in development of diagnostic tools
Externí odkaz:
https://doaj.org/article/afc0de4336cf451382774296cb7f276f
Publikováno v:
Pharmaceutics, Vol 16, Iss 4, p 461 (2024)
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality around the globe. To address this public health burden, innovative therapeutic agents are being developed to specifically target molecular and genetic markers. Various
Externí odkaz:
https://doaj.org/article/c8643a9b1e224438b00972237e977377
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 163, Iss , Pp 114757- (2023)
The circulatory half-life of recombinant therapeutic proteins is an important pharmacokinetic attribute because it determines the dosing frequency of these drugs, translating directly to treatment cost. Thus, recombinant therapeutic glycoproteins suc
Externí odkaz:
https://doaj.org/article/a560f677b3cf4a09bd98741e1d085795
Autor:
Francesco Angotzi, Marco Petrella, Tamara Berno, Gianni Binotto, Giorgia Bonetto, Antonio Branca, Marco Carraro, Chiara Adele Cavaretta, Alessandro Cellini, Fabio D’Amore, Laura Forlani, Ilaria Gianesello, Carmela Gurrieri, Silvia Imbergamo, Federica Lessi, Antonio Maroccia, Federica Mazzetto, Laura Pavan, Sara Pezone, Francesco Piazza, Stefano Pravato, Valeria Ruocco, Greta Scapinello, Fabrizio Vianello, Renato Zambello, Ivan Zatta, Simone Zoletto, Andrea Padoan, Livio Trentin, Andrea Visentin
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the rate of symptomatic SARS-CoV-2 infection in patients at increased risk of inadequate response to vaccination. However, Tixagevimab/Cilgavimab was tested in a few studie
Externí odkaz:
https://doaj.org/article/1d24015006414524bad71f3a10a0bffd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.